bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾

9ÔÂ25ÈÕ£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾Ðû²¼£¬£¬£¬£¬£¬¹«Ë¾×ÔÖ÷Ñз¢µÄ¡¸TRD205£¨AT2RÞ׿¹¼Á£©¡¹ÒÑÏòÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨FDA£©Ìá½»ÊÔÑéÓÃÐÂÒ©£¨IND£©ÉêÇë²¢»ñµÃÊÜÀí¡£¡£¡£¡£¡£¡£

TRD205ΪѪ¹ÜÖ÷ÒªËØIIÐÍ2ÊÜÌ壨AT2R£©µÄÐÂÐÍÞ׿¹¼Á£¬£¬£¬£¬£¬Ä⿪·¢ÓÃÓÚÖÎÁÆÉñ¾­²¡ÀíÐÔÌÛÍ´¡£¡£¡£¡£¡£¡£Éñ¾­²¡ÀíÐÔÌÛÍ´ÊÇÊ®·Ö³£¼ûµÄÒ»ÀàÂýÐÔÌÛÍ´£¬£¬£¬£¬£¬ÁÙ´²ÌåÏÖÖØ´ó¶àÑù£¬£¬£¬£¬£¬´ó¶¼²¡³ÌÁè¼Ý3¸öÔ¡£¡£¡£¡£¡£¡£»£»£»£»£»¼ÕßÌÛÍ´ÌØÕ÷²»È«Ïàͬ£¬£¬£¬£¬£¬ÒÔ×ÆÉÕ»ò»ðÉÕÑùÌÛÍ´¡¢µç»÷ÑùÍ´¡¢Õë´ÌÑùÍ´¡¢ËºÁÑÑùÍ´½Ï¶à¼û¡£¡£¡£¡£¡£¡£Éñ¾­Í´ÑÏÖØÓ°Ï컼ÕßµÄÉúÑÄÖÊÁ¿£¬£¬£¬£¬£¬¸ø»¼Õß´øÀ´ÎÞ·¨ÈÌÊܵÄÍ´¿à£¬£¬£¬£¬£¬Ñо¿Åú×¢£¬£¬£¬£¬£¬Í¨Ë×ÈËȺÖÐÉñ¾­²¡ÀíÐÔÌÛÍ´µÄ·¢²¡Âʸߴï8%¹¡£¡£¡£¡£¡£¡£ÏÖÔÚÁÙ´²Ò©ÎïÒÔ°¢Æ¬ÀàºÍ°ÐÏòÀë×ÓÃÅ¿ØͨµÀÒ©ÎïΪÖ÷£¬£¬£¬£¬£¬½öÄÜʹËÄ·ÖÖ®Ò»»¼Õß»ñÒæ¡£¡£¡£¡£¡£¡£AT2R±í´ïÓÚÍâÖܨuƤ·ô¾ÞÊÉϸ°û£¨MΦs£©£¬£¬£¬£¬£¬ÆäÆô¶¯ÊÇÉñ¾­ËðÉ˲¿Î»Í´¾õÃô»¯µÄÒªº¦´¥·¢ÒòËØ£¬£¬£¬£¬£¬MΦsÖÐAT2RµÄÆô¶¯´¥·¢»îÐÔÑõ¨uµªµÄ±¬·¢£¬£¬£¬£¬£¬´Ó¶øÒýÆ𱳸ùÉñ¾­½Ú£¨DRG£©¸ÐÊÜÉñ¾­Ôª¸ÆÄÚÁ÷£¬£¬£¬£¬£¬ÓÕµ¼ÌÛÍ´³¬Ãô·´Ó¦¡£¡£¡£¡£¡£¡£

1. Thomas R. Tolle. Challenges with current treatment of neuropathic pain. European journal of pain supplements. 2010; 4: 161-165